Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Alba Hernández García"'
Autor:
Alba Hernández-García, Lenka Marková, María Dolores Santana, Jitka Prachařová, Delia Bautista, Hana Kostrhunová, Vojtěch Novohradský, Viktor Brabec, José Ruiz, Jana Kašpárková
Publikováno v:
Inorganic Chemistry. 62:6474-6487
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::244db7740bc41de5ab9c27ab54a7a178
https://doi.org/10.1021/acs.inorgchem.3c00501
https://doi.org/10.1021/acs.inorgchem.3c00501
Autor:
Enrique Ortega, José Ruiz, M. Dolores Santana, Fernando Gandía-Herrero, Alba Hernández-García, Francisco J. Ballester, Delia Bautista, Samanta Hernández-García, M. Alejandra Guerrero-Rubio
Publikováno v:
Inorganic Chemistry Frontiers. 8:141-155
This work reports the synthesis and characterization of some novel osmium(II) complexes with potential as anticancer drugs tested in vitro and in vivo. The complexes have a structure [(η6-p-cym)Os(C^N)(X)]0/+, where the C^N ligand is deprotonated 2-
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::05867f0d49b82df410bdf055e1278d95
https://doi.org/10.1039/c9qi01704f
https://doi.org/10.1039/c9qi01704f
Autor:
Alba Hernández-García, Lenka Markova, María Dolores Santana, Jitka Pracharova, Viktor Brabec, José Ruiz, Jana Kasparkova
Publikováno v:
SSRN Electronic Journal.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::546c05701faaf67c30c082298782cdfa
https://doi.org/10.2139/ssrn.4221729
https://doi.org/10.2139/ssrn.4221729
Publikováno v:
Dermatology Online Journal. 25
Anti-programmed cell death (PD)-1 therapies in metastatic tumors have a high incidence of immune adverse events, including cutaneous manifestations such as vitiligo-like lesions. This side effect is associated with increased survival and it is a clin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0336991917ef5be9eea94d0473f4e6a2
https://doi.org/10.5070/d32512046728
https://doi.org/10.5070/d32512046728
Autor:
María Jesús Lamas, Rafael López, Borja Franco, Bibiana Sanchez, Goretti Duran, Mar Lale, Manuel Touris, Nieves Mayo, Juan Cueva, Alicia Mosquera, Beatriz Bernardez, Sara Blanco, Alba Hernández García, Elena López
Publikováno v:
Journal of Clinical Oncology. 36:e18872-e18872
e18872Background: Most data on infusion related reactions (IRR) come from clinical trials. Its severity and management are issues addressed in many studies, however, the impact in real life in term...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1757fe7906d828a10d3fa913e68aad7f
https://doi.org/10.1200/jco.2018.36.15_suppl.e18872
https://doi.org/10.1200/jco.2018.36.15_suppl.e18872
Autor:
Lourdes Calera, Miguel A Ubieto, Maite Soria, Carlos Hördnler, Antonio Antón, Luis Sarría, Roberto A. Pazo Cid, José María Artigas, Javier Fuentes, Elena Barrao, M. Lanzuela, Isabel Pajares, Javier Martínez Trufero, Ana Cebollero, Alba Hernández García, Jorge Hernando Cubero, Angel Artal, Teresa Puertolas, Javier Banzo, Alejandro Serrablo
Publikováno v:
Journal of Clinical Oncology. 32:4104-4104
4104 Background: SB remains since 2007 the only drug that improves overall survival (OS) of aHCC pts. Predicting early response to SB could save costs and toxicity. PET has never been properly test...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::69b422b085cff8ea6bf06caf5a5a3e0b
https://doi.org/10.1200/jco.2014.32.15_suppl.4104
https://doi.org/10.1200/jco.2014.32.15_suppl.4104
Autor:
Javier Martinez-Trufero, Lourdes Calera, Isabel Pajares, Antonio Antón, Alba Hernández García, Ana Cebollero
Publikováno v:
Journal of Clinical Oncology. 31:e21509-e21509
e21509 Background: Trabectedin (Yondelis) is the first marine-derived antineoplastic drug approved in Europe for the treatment of patients with recurrent ASTS or for patients unsuited to receive anthracyclines and ifosfamide. We retrospectively analy
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::aefac82580bba3d36732f2b5964817ff
https://doi.org/10.1200/jco.2013.31.15_suppl.e21509
https://doi.org/10.1200/jco.2013.31.15_suppl.e21509